Actively Recruiting

Phase 2
Phase 3
Age: 18Years +
All Genders
Healthy Volunteers
ID05334485

Pyridostigmine Efficacy and Safety for Treatment of Ileus After Colorectal Surgery (PESTI Trial)

Led by Stefan Holubar MD MS FACS, FASCRS · Updated on 2026-01-07

50

Participants Needed

1

Research Sites

4 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the safety and effectiveness of pyridostigmine as a rescue treatment for postoperative ileus in patients who have undergone elective colorectal surgery. This randomized, double-blind, placebo-controlled trial involves adults with benign or malignant colonic or rectal disease who develop postoperative ileus, characterized by symptoms like bloating and absence of bowel movements for at least 48 hours after surgery. The study aims to compare pyridostigmine with placebo alongside standard care to better understand its impact on bowel function recovery. Participants will be randomly assigned to one of two groups: one receiving 60 mg of oral pyridostigmine bromide every 12 hours, and the other receiving an oral starch placebo every 12 hours. Treatment will continue from the time postoperative ileus is diagnosed until the return of bowel function or for a maximum of 48 hours. Side effects will be monitored using a specific side effects scale completed at enrollment and after each dose. During the study, participants will be closely monitored for the time until the first passage of gas and stool, tolerance of solid food, and any complications or need for re-operation or hospital readmission within 30 days after surgery. Safety assessments include surveys for side effects after each dose. The total participation period includes follow-up for up to 30 days to capture important recovery and complication outcomes related to postoperative ileus treatment.

CONDITIONS

Brief Title

Pyridostigmine Efficacy and Safety for Treatment of Ileus After Colorectal Surgery

Who Can Participate

Age: 18Years +
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged 18 years and older with benign or malignant colonic or rectal disease
  • Underwent elective laparoscopic, robotic, or open colorectal resection with or without ostomy
  • Developed postoperative ileus defined by bloating with or without nausea/vomiting, no passage of flatus or stool for at least 48 hours, requiring return to NPO after initial diet attempts
  • Radiographic confirmation of postoperative ileus by abdominal X-ray or CT scan
  • ECOG performance status less than 4
  • Normal organ function based on lab tests including hemoglobin, white blood cell count, platelet count, liver enzymes, bilirubin, and creatinine
Not Eligible

You will not qualify if you...

  • Evidence of bowel obstruction on imaging
  • Intraabdominal septic complications such as abscess, peritonitis, or anastomotic leak
  • Surgery involving only small bowel or ostomy without colon or rectal resection
  • ASA score of 5
  • Pregnant or breastfeeding females
  • Current use of other investigational agents or medications affecting bowel motility
  • History of allergy to pyridostigmine or similar drugs
  • Uncontrolled illnesses including myasthenia gravis, asthma, COPD, heart failure, unstable angina, arrhythmia, renal or hepatic failure, gastroparesis, short bowel syndrome, bowel dysmotility, chronic constipation, peritoneal carcinomatosis, or psychiatric/social conditions limiting compliance

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Treatment

Duration - Up to 48 hours

Participants receive oral doses of pyridostigmine bromide or placebo every 12 hours from diagnosis of postoperative ileus until return of bowel function or for a maximum of 48 hours.

Multiple administrations every 12 hours

Trial Site Locations

Total: 1 location

1

Cleveland Clinic Main Campus

Cleveland, Ohio, United States, 44195

Actively Recruiting

Loading map...

Research Team

S

Stefan D Holubar

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

Dexamethasone in the Prevention of Post-spinal Paralytic Ile...

Postoperative Ileus

Actively Recruiting

1 location

A Multicenter, Randomized Controlled Trial to Evaluate the E...

Colorectal Cancer

Actively Recruiting

1 location

Gastrointestinal Stimulation As a Treatment of Postoperative...

Postoperative Ileus

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here